Compare BIO-TECHNE Corp (TECH) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs State Street Technology Select Sector SPDR ETF — how do they compare? BIO-TECHNE Corp trades at $71.63 (market cap $11.16B), while State Street Technology Select Sector SPDR ETF trades at $180.33. The key difference: BIO-TECHNE Corp pays a 0.45% dividend while State Street Technology Select Sector SPDR ETF pays none, and BIO-TECHNE Corp is trading nearer its 52-week high, State Street Technology Select Sector SPDR ETF nearer its low. Which is the better fit depends on your goals.
| TECH | XLK | |
|---|---|---|
Market Cap | $11.16B | — |
Sector | Health | Sector/Thematic |
52-Week High | $72.12 | $198.21 |
52-Week Low | $43.31 | $127.49 |
Enterprise Value | $11.24B | — |
Dividend Yield | 0.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
XLK, the Technology Select Sector SPDR Fund, trades at $175.71 with a slight 0.07% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund has delivered strong year-to-date performance, up 33% as of July 2, 2026 (ETF Trends), but faces concentration risks in mega-cap tech holdings. Recent news highlights ongoing institutional interest in tech ETFs amid robust earnings expectations for the sector.
The outlook for XLK remains tied to technology sector strength, with Q2 earnings expected to show 23.3% growth for the S&P 500 (ETF Trends, July 13, 2026). Key risks include sector concentration and market volatility. Wall Street sentiment is positive due to strong fundamentals, but investors should monitor earnings results and Fed policy impacts on growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
